Why the study?
Does ML355 inhibit thrombus formation without significantly impairing hemostasis in preclinical models?
Population
Human platelets and mouse models of thrombosis and hemostasis
Comparison
ML355 (selective 12-LOX inhibitor) vs Aspirin and implied vehicle/control
Design
Preclinical
Authors
Loading...
12-LOX inhibition attenuates thrombosis in mice; leaves open whether selective targeting will prove effective and safe in humans.
Does ML355 inhibit thrombus formation without significantly impairing hemostasis in preclinical models?
The selective 12-LOX inhibitor ML355 reduces thrombus formation in vivo without significantly increasing bleeding risk in preclinical models, suggesting a potential new class of antiplatelet therapy.
Adili et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: